Proactiveinvestors recommends
Additional Information
Market: AIM
Sector: Software & Computer Services
EPIC: MDST
Latest Price: 0.00p  (0,00%)
52-week High: 10.50p
52-week Low: 0.25p
1 year chart
digital-look imported chart image
1 day chart
digital-look imported chart image
Watchlist/Portfolio

Add to watchlist:

Only registered members can add into watchlist !

Register here !
Medicsight
www.medicsight.com

Medicsight Plc is a UK-headquartered research driven developer of computer-aided detection (CAD) and image analysis software for the medical imaging market, engaged in the development and commercialization of medical imaging software, which analyses Computer Tomography (CT) scans for the early detection and measurement of colon cancer polyps and lung cancer lesions. The Company is also engaged in the research and development of other medical software applications and devices with potential applications in the medical imaging, detection and diagnosis sectors. On June 28, 2007, Medicsight PLC acquired the entire share capital of Medicexchange PTY Ltd from Medicexchange (International) Ltd.

Full Medicsight profile here
Pdf

Medicsight promotes CFO Troy Robinson to board position

19th Mar 2010, 7:50 am Medicsight promotes CFO Troy Robinson to board position

Medicsight PLC (AIM: MDST), specialised in Computer-Aided Detection (CAD) and image analysis software which assists in the early detection and diagnosis of disease, said it appointed Troy Robinson to the board as chief financial officer and company secretary with immediate effect.

Robinson joined Medicsight in February 2007 as group financial controller after a successful career with IVAX Pharmaceuticals and HP Foods. He was appointed CFO in February 2009, as a non board position.

During his tenure with Medicsight, he has played a pivotal role in both the Medicsight IPO and the subsequent global expansion of the finance function, the group said in a statement.

Medicsight’s CAD software automatically highlights suspicious areas on computerised tomography (CT) scans of the colon and lung, helping radiologists to identify, measure and analyse potential disease and early indicators of disease.

Its software has been developed using one of the world's largest and most population diverse databases of verified patient CT scan data. Medicsight's ColonCAD and LungCAD software products are integrated with the advanced 3D visualisation workstations of several major imaging equipment partners.

Medicsight currently has a pre-market notification for the ColonCAD API 3.1 product pending with the US Food and Drug Administration and is working towards fulfilling the regulator’s request for additional information prior to the 21 June 2010 deadline.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.